HIGH DOSE IFN ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA. RESULTS AFTER 31 MONTHS MEDIAN FOLLOW-UP

被引：0
|
作者：
Muggiano, A. [1 ]
Mulas, C. [1 ]
Fiori, B. [1 ]
Liciardi, G. [1 ]
Pintus, M. [1 ]
Tanca, L. [1 ]
Tedde, A. [1 ]
Turno, R. [1 ]
Desogus, A. [1 ]
机构：
[1] Osped Oncolog A Businco, Div Med Oncol 1, Cagliari, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma
    Hillner, BE
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S18 - S21
  • [2] Adjuvant interferon alfa-2b for high-risk melanoma
    Retsas, S
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1968 - 1968
  • [3] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
    Jonasch, E
    Kumar, UN
    Linette, GP
    Hodi, FS
    Soiffer, RJ
    Ryan, BF
    Sober, AJ
    Mihm, MC
    Tsao, H
    Langley, RG
    Cosimi, BA
    Gadd, MA
    Tanabe, KK
    Souba, W
    Haynes, HA
    Barnhill, R
    Osteen, R
    Haluska, FG
    CANCER JOURNAL, 2000, 6 (03): : 139 - 145
  • [4] Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up
    Elias, Elias George
    Zapas, John L.
    Beam, Sandra L.
    Culpepper, William J.
    MELANOMA RESEARCH, 2007, 17 (05) : 310 - 315
  • [5] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma
    Agarwala, Sanjiv S.
    Gray, Robert J.
    Wong, Michael K. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E82 - E83
  • [6] Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, TJ
    Borden, EC
    Blum, RH
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 7 - 17
  • [7] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma Reply
    Pectasides, Dimitrios
    Dafni, Urania
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E84 - E84
  • [8] Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Weichenthal, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : E70 - E70
  • [9] Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma Reply
    Pectasides, Dimitrios
    Dafni, Urania
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : E71 - E71
  • [10] Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma
    Hansson, J.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Nilsson, B.
    Stierner, U.
    von der Maase, H.
    EJC SUPPLEMENTS, 2007, 5 (06): : 4 - 4
12345